{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:26:14Z","timestamp":1792844774241,"version":"4.5.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Smoldering multiple myeloma (SMM) is an asymptomatic precursor condition to multiple myeloma (MM). The prevalence of SMM is 0.5% in persons over 40 years old; it is higher in men than women and increases with age. When SMM is diagnosed, a thorough diagnostic workup is necessary to exclude myeloma-defining events and stratify patients according to risk of progression to MM. While close monitoring for progression remains the best management for most patients with SMM, in this article, we discuss if treatment initiation before myeloma-defining events occur might be relevant in selected high-risk cases. Two randomized clinical trials have shown a clinical benefit of initiating treatment at the SMM stage, whereof 1 showed an overall survival benefit for those receiving treatment. We discuss various risk stratification models in SMM, important treatment trials, and ongoing trials. Finally, we present how to approach the clinical management of patients with SMM.<\/jats:p>","DOI":"10.1182\/hematology.2022000355","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:13:27Z","timestamp":1670602407000},"page":"551-559","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["The consultant's guide to smoldering multiple myeloma"],"prefix":"10.1182","volume":"2022","author":[{"given":"Sigrun","family":"Thorsteinsdottir","sequence":"first","affiliation":[{"name":"1 Faculty of Medicine, University of Iceland, Reykjavik, Iceland"},{"name":"2 Department of Hematology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigurdur Yngvi","family":"Kristinsson","sequence":"additional","affiliation":[{"name":"1 Faculty of Medicine, University of Iceland, Reykjavik, Iceland"},{"name":"3 Landspitali University Hospital, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"5","key":"2022121313295306900_hem2022000355C1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","article-title":"Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies","volume":"11","author":"R\u00f6gnvaldsson","year":"2021","journal-title":"Blood Cancer J"},{"issue":"12","key":"2022121313295306900_hem2022000355C2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"25","key":"2022121313295306900_hem2022000355C3","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"3","key":"2022121313295306900_hem2022000355C4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clml.2014.09.004","article-title":"Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis","volume":"15","author":"Go","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"2022121313295306900_hem2022000355C5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","article-title":"The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma","volume":"1","author":"Sigurdardottir","year":"2015","journal-title":"JAMA Oncol"},{"key":"2022121313295306900_hem2022000355C6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2021-148617","article-title":"Prevalence of smoldering multiple myeloma: results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study","volume":"138","author":"Thorsteinsdottir","year":"2021","journal-title":"Blood"},{"issue":"15, suppl","key":"2022121313295306900_hem2022000355C7","doi-asserted-by":"crossref","first-page":"e13064","DOI":"10.1200\/JCO.2019.37.15_suppl.e13064","article-title":"Demographic characteristics of smoldering multiple myeloma patients: a hospital-based study including 11,643 patients","volume":"37","author":"Chamoun","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"2022121313295306900_hem2022000355C8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"12","key":"2022121313295306900_hem2022000355C9","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","article-title":"Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana","volume":"82","author":"Landgren","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"2022121313295306900_hem2022000355C10","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0025-6196(11)61090-2","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan","volume":"82","author":"Iwanaga","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"2022121313295306900_hem2022000355C11","doi-asserted-by":"crossref","first-page":"e486","DOI":"10.1038\/bcj.2016.100","article-title":"Prevalence, incidence and survival of smoldering multiple myeloma in the United States","volume":"6","author":"Ravindran","year":"2016","journal-title":"Blood Cancer J"},{"issue":"16, suppl","key":"2022121313295306900_hem2022000355C12","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1200\/JCO.2022.40.16_suppl.8045","article-title":"African American patients with smoldering multiple myeloma may have a lower risk of progression compared to white patients","volume":"40","author":"Akhlaghi","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"2022121313295306900_hem2022000355C13","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2022121313295306900_hem2022000355C14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"11","key":"2022121313295306900_hem2022000355C15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-018-0144-x","article-title":"Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma","volume":"8","author":"Atrash","year":"2018","journal-title":"Blood Cancer J"},{"issue":"6","key":"2022121313295306900_hem2022000355C16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression","volume":"32","author":"Fern\u00e1ndez de Larrea","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2022121313295306900_hem2022000355C17","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1002\/ajh.26062","article-title":"Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression","volume":"96","author":"Gran","year":"2021","journal-title":"Am J Hematol"},{"issue":"7","key":"2022121313295306900_hem2022000355C18","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi","year":"2016","journal-title":"Blood Cancer J"},{"issue":"12","key":"2022121313295306900_hem2022000355C19","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/bloodadvances.2018016998","article-title":"Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling","volume":"2","author":"Wu","year":"2018","journal-title":"Blood Adv"},{"issue":"11","key":"2022121313295306900_hem2022000355C20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41408-021-00569-2","article-title":"Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"issue":"34","key":"2022121313295306900_hem2022000355C21","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"21","key":"2022121313295306900_hem2022000355C22","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2022121313295306900_hem2022000355C23","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2022121313295306900_hem2022000355C24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41467-020-20524-2","article-title":"The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma","volume":"12","author":"Boyle","year":"2021","journal-title":"Nat Commun"},{"issue":"suppl 1","key":"2022121313295306900_hem2022000355C25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2021-146535","article-title":"Circulating tumor cells (CTCs) in smoldering and active multiple myeloma (MM): mechanism of egression, clinical significance and therapeutic endpoints","volume":"138","author":"Garc\u00e9s","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2022121313295306900_hem2022000355C26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41408-021-00505-4","article-title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2022121313295306900_hem2022000355C27","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood-2021-152317","article-title":"Defining genomic probability of progression to identify low-risk smoldering multiple myeloma","volume":"138","author":"Aktas-Samur","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313295306900_hem2022000355C28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1182\/blood-2021-150092","article-title":"Definition and clinical significance of the MGUS-like phenotype: a study in 5,114 patients (pts) with monoclonal gammopathies","volume":"138","author":"Burgos","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2022121313295306900_hem2022000355C29","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2022121313295306900_hem2022000355C30","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"2022121313295306900_hem2022000355C31","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"2022121313295306900_hem2022000355C32","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"},{"issue":"22","key":"2022121313295306900_hem2022000355C33","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/bloodadvances.2017005934","article-title":"Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma","volume":"1","author":"Mailankody","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"2022121313295306900_hem2022000355C34","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jamaoncol.2021.3971","article-title":"Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: a phase 2 nonrandomized controlled trial","volume":"7","author":"Kazandjian","year":"2021","journal-title":"JAMA Oncol"},{"issue":"suppl 1","key":"2022121313295306900_hem2022000355C35","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood-2021-148423","article-title":"Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with KRd and maintenance with Rd","volume":"138","author":"Mateos","year":"2021","journal-title":"Blood"},{"key":"2022121313295306900_hem2022000355C36","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2021-149787","article-title":"A phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma","volume":"138","author":"Nadeem","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2022121313295306900_hem2022000355C37","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2022121313295306900_hem2022000355C38","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1182\/blood-2019-123205","article-title":"A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM)","volume":"134","author":"Manasanch","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2022121313295306900_hem2022000355C39","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/jamaoncol.2020.5585","article-title":"Assessment of discordance among smoldering multiple myeloma risk models","volume":"7","author":"Hill","year":"2021","journal-title":"JAMA Oncol"},{"issue":"11","key":"2022121313295306900_hem2022000355C40","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1080\/10428194.2021.1938032","article-title":"The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt","volume":"62","author":"Mohyuddin","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2022121313295306900_hem2022000355C41","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1080\/10428194.2021.1951723","article-title":"Should high risk smoldering myeloma be treated outside a clinical trial: NO","volume":"62","author":"Gertz","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2022121313295306900_hem2022000355C42","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.3324\/haematol.2021.278519","article-title":"2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde","volume":"106","author":"Musto","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"2022121313295306900_hem2022000355C43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/PPO.0000000000000350","article-title":"Smoldering multiple myeloma: to treat or not to treat","volume":"25","author":"Kapoor","year":"2019","journal-title":"Cancer J"},{"issue":"6","key":"2022121313295306900_hem2022000355C44","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"2022121313295306900_hem2022000355C45","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2014.75","article-title":"Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma","volume":"28","author":"Merz","year":"2014","journal-title":"Leukemia"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/551\/2022872\/551thorsteinsdottir.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/551\/2022872\/551thorsteinsdottir.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T13:34:20Z","timestamp":1670938460000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/551\/493540\/The-consultant-s-guide-to-smoldering-multiple"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000355","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}